Heather 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

If your patients have been calling about difficulty filling their Heather 28 Day prescriptions, you're not alone. Pharmacy-level availability issues for norethindrone 0.35 mg progestin-only pills have been an ongoing frustration for patients and prescribers alike. This briefing covers the current landscape, prescribing implications, and practical steps to keep your patients on effective contraception in 2026.

Current Supply Status: What the Data Shows

As of 2026, norethindrone 0.35 mg (the active ingredient in Heather) is not listed on either the FDA Drug Shortage Database or the ASHP shortage list. National manufacturing appears adequate — multiple companies produce the drug, and the API supply chain for norethindrone is well-established.

The access difficulties your patients are experiencing are primarily pharmacy-level distribution issues, not a systemic supply shortage. This is a clinically important distinction because the solutions are different: rather than managing clinical alternatives, the priority is helping patients navigate pharmacy access.

Root Causes of Pharmacy-Level Unavailability

Several structural factors contribute to the mismatch between adequate national supply and patient-level access difficulties:

• Generic market fragmentation: More than a dozen brand names (Heather, Camila, Errin, Jencycla, Nora-Be, Incassia, Lyza, Sharobel, Jolivette, and others) all contain norethindrone 0.35 mg. Pharmacies stock only one or two at a time based on wholesaler pricing. If your prescription is brand-specific and the pharmacy carries a different brand, the prescription cannot be filled without prescriber intervention.
• Wholesaler allocation practices: Distributors allocate inventory based on purchase history. During demand spikes, smaller or independent pharmacies may receive reduced allocations of specific brands, creating intermittent local stockouts.
• Insurance formulary changes: When a PBM shifts its preferred norethindrone brand, pharmacies adjust their stocking. Patients whose pharmacy no longer stocks their prescribed brand face unnecessary barriers even though an equivalent is on the shelf.
• Residual supply chain fragility: COVID-19-era disruptions to pharmaceutical API sourcing and manufacturing have not fully resolved for all oral contraceptive products. While norethindrone POPs are more stable than combination formulations, regional gaps persist.

Clinical Implications for Prescribers

Norethindrone 0.35 mg POPs have a narrow 3-hour missed-pill window — much tighter than the 12-hour window for most combination oral contraceptives. This means that even a 1-2 day delay in filling a prescription due to stocking issues can result in a gap in contraceptive efficacy requiring backup contraception for 48 hours. For your patients, this is not a minor inconvenience.

Additionally, many patients taking the mini-pill cannot switch to combination pills while they wait. These include patients who are breastfeeding, have a history of VTE or stroke, have migraines with aura, uncontrolled hypertension, or smokers over 35. For these patients, maintaining continuous norethindrone access is particularly important.

Prescribing Strategies to Maximize Patient Access

The following prescribing practices will substantially reduce your patients' risk of running out of medication:

1. Prescribe by generic name. Write "norethindrone 0.35 mg tablets" rather than "Heather" or any other brand name. This allows pharmacists to dispense any in-stock equivalent.
2. Use DAW-0 (allow substitution). Explicitly permit any AB-rated equivalent to be dispensed. Avoid DAW-1 designations unless clinically required.
3. Write for 90-day supplies when insurance permits. Reducing refill frequency reduces the risk of encountering a stocking gap at a critical time.
4. Educate patients proactively. Tell patients at the time of prescribing that they may encounter pharmacy stocking issues, and let them know that Camila, Errin, Nora-Be, and other brands are equivalent substitutes.
5. Refer patients to pharmacy-finding tools. Rather than having your staff field pharmacy availability calls, direct patients to use medfinder or similar services that identify in-stock pharmacies.

38,596+ patients found their medications in stock

38K+

Find Heather 28 Day In Stock Today →

Therapeutic Alternatives When Norethindrone POPs Are Unavailable

If a patient truly cannot find any norethindrone 0.35 mg brand, the following alternatives are appropriate depending on the clinical context:

• Slynd (drospirenone 4 mg): A progestin-only pill with a 24-hour missed-pill window. May be more expensive; check formulary coverage. Appropriate for patients who cannot take estrogen.
• Opill (norgestrel 0.075 mg): The only OTC progestin-only pill; available without prescription for ~$19.99/month. An option for patients who need to bridge a gap while awaiting a fill.
• LARC (for persistent access issues): Patients with recurring access problems may benefit from a long-acting reversible contraceptive discussion — hormonal IUD or etonogestrel implant — to eliminate ongoing pharmacy dependency.

Supporting Your Practice

medfinder for Providers offers pharmacy availability data that can reduce the burden on your clinical staff. Rather than fielding patient calls about pharmacy availability, direct patients to medfinder's provider tools to streamline the process of locating in-stock pharmacies.

Skip the calls, skip the stress.

Find Heather 28 Day In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Summary for Prescribers

Heather 28 Day is not in a formal shortage, but pharmacy access is genuinely inconsistent. Switching your prescriptions to generic name with substitution permitted, educating patients at the point of prescribing, and recommending patient-facing pharmacy-finding tools are the most effective interventions available. For a comprehensive guide to helping your patients locate Heather and its equivalents, see our full provider guide.